Cadherin (CDH)16/kidney-specific-cadherin was first described as a kidney-specific adhesion molecule and thereafter found expressed also in the thyroid gland. We show here that CDH16 fully colocalizes with CDH1/E-cadherin on the basolateral plasma membrane of mouse and human thyrocytes. In thyrocyte cultures, the expression of CDH16 is dependent upon TSH, as other thyroid differentiation markers. In the developing mouse thyroid, CDH16 is expressed at embryonic day 10.5, 1-2 d after the main thyroid-specific transcription factors involved in thyroid cell differentiation. In human thyroid carcinomas, as determined by quantitative RT-PCR, CDH16 expression decreases in papillary, follicular, and anaplastic thyroid carcinomas, and the decrease is more pronounced than that of CDH1. Moreover, by immunofluorescence and confocal microscopy, it appears that although CDH16-negative tumor cells may still be positive for CDH1, CDH1-negative cells are also negative for CDH16, indicating a more extensive loss of the latter and suggesting that CDH16 loss might precede that of CDH1. Loss of CDH16 appears to be a marker of epithelialmesenchymal transition as indicated by its decrease in cultured thyroid cells after TGF-␤ treatment. Finally, the decrease in CDH16 is paralleled in part by the decrease in ␣ B-crystallin, which was proposed to mediate the interaction of CDH16 cytosolic tail with the cell cytoskeleton. In conclusion, CDH16 is a thyroid-selective and hormone-dependent adhesion protein that might play a role during thyroid development and that may be a useful marker to monitor thyroid carcinomas. (Endocrinology 153: 522-534, 2012) 
C
adherins (CDH) belong to a superfamily of glycoproteins that mediate calcium-dependent cell-cell adhesion. The homotypic, homophilic interactions between extracellular regions are characteristic of cadherins and are essential for embryonic development, normal cell function, and the preservation of tissue integrity (1) (2) (3) . The extracellular domains of cadherins show a plethora of divergent structural arrangements, and the anchor to the cell membrane, which is usually a transmembrane region, can be a lipid moiety. Also, the length of cytoplasmic regions is variable and allows specific interactions with respective intracellular binding partners (4) . The prototype of classical cadherins, CDH1 (uvomorulin, E-cadherin), is a transmembrane protein expressed in differentiated epithelia that binds p120 and ␤-or ␥-catenin with its cytosolic tail (1) . CDH1 was found expressed in the embryonic and in the adult thyroid gland together with another classical cadherin, CDH4 (R-cadherin) (5) (6) (7) .
It was demonstrated that the thyroid also expresses CDH16 (7) , which was first identified in rabbit as a cad-herin only expressed in the kidney and therefore named kidney specific (Ksp) (8) . CDH16 belongs to a family of cadherins that is defined by seven extracellular cadherin repeats (seven domains) and a short intracellular domain that does not interact with any of the catenins (8, 9) but might interact with the ␣ B-crystallin (CRYAB) (10) . In rabbit kidneys, CDH16 was localized on the basolateral membranes of both proximal and distal tubules (11) , but the most prominent expression was seen on distal tubules and collecting ducts of human adult kidney (12) . The specificity of expression in the kidney and genitourinary tract was confirmed after cloning of the human and mouse isoforms. Transcript hybridization of CDH16 was not observed in RNA isolated from several tissues, even after extensive overexposure (13) , and CDH16 promoter directed kidney-specific expression in transgenic mice (14 -16) . The adhesive strength of CDH16 was tested in vitro by an aggregation assay, which indicated that the aggregation indices of CDH16-expressing CHO cells were very similar to those of CDH1-expressing CHO cells (17) . It was proposed that CDH16, likely in concert with other cadherins, might be required in the differentiation process of kidney and possibly of lung and sex duct epithelia, where it is transiently expressed in the embryonic life (18) . During human kidney development, RNA expression of CDH16 was detected at the ninth week of gestation (12) . Down-regulation of cadherins has been reported to occur in carcinogenesis and is believed to be associated with tumor progression in a variety of human carcinomas (19 -22) . Loss of adhesiveness and cell detachment are important for cancer development. Therefore, decreased expression or even loss of cadherins, either quantitatively or qualitatively, may lead to the development of epithelial tumor, invasion, and metastasis (23) . Changes in the CDH1/catenin complex were observed in thyroid tumors. These tumors comprise a broad spectrum of lesions with different degrees of malignancy from benign adenomas, which are not invasive and very well differentiated, to the undifferentiated anaplastic thyroid carcinomas (ATC), which are very aggressive and often fatal. Papillary thyroid carcinoma (PTC) and follicular thyroid carcinomas (FTC), the most common forms of thyroid cancer, represent intermediate forms of neoplasia being rather differentiated and having a good prognosis. More than 90% of all thyroid cancers, including PTC and FTC, derive from the thyroid follicular cell. ATC may arise de novo or derive from preexisting PTC or FTC (24, 25) . As in many other cancers, the expression of CDH1 is almost unaltered in benign adenomas, variably reduced in differentiated thyroid carcinomas, like PTC and FTC, and severely reduced or completely absent in undifferentiated thyroid tumors, like ATC (5, 26, 27) . Decreased CDH1 expression might contribute to the loss of cellular differentiation involved in the complex mechanism of progression of thyroid tumors. CDH1 loss seems to be also associated with the metastatic spread of thyroid carcinomas, and it has been proposed as a marker for the prognosis of these tumors (28, 29) .
CDH16, like CDH1, appears to have reduced expression in human tumors. This is the case of renal cell carcinomas (RCC), which possibly originate from epithelial kidney tubular cells, in which the expression of CDH16 is completely abrogated (12) . The same apparently is not true for chromophobe RCC and for renal oncocytomas, indicating a nonuniversal role of CDH16 as tumor suppressor (30) .
We investigated here the expression of CDH16 in mouse and human thyroids. We demonstrate that it colocalizes with CDH1 and that its expression is dependent upon TSH, at least in cultured cells. We show that during mouse thyroid development, the expression of CDH16 starts at embryonic day (E)10.5 and is maintained in the adulthood. We also report that CDH16 expression is down-regulated in all types of thyroid carcinomas and that its down-regulation precedes and is more severe than that of CDH1. Moreover, we show reduced expression of CDH16 in FRTL5 thyroid cells after TGF-␤ stimulation, which is known to induce epithelial-mesenchymal transition (EMT) (6) . Finally, we analyze the loss of CDH16 in the light of the decrease in CRYAB expression.
Materials and Methods

Antibodies
The following antibodies were used: mouse monoclonal anti-CDH1 
Cell culture
FRTL5 and PC Cl3 rat thyroid cells (31) (32) (33) were grown in plastic culture dishes (Costar, Corning, Inc., The Netherlands) in Coon's modified Ham's F-12 medium supplemented with 5% calf serum (HyClone, Thermo Scientific, Erembodegem, Belgium) and a mixture of six hormones and growth factors (6H), (32) . FRT thyroid cells (31, 33) were cultured in Coon's modified Ham's F-12 medium supplemented with 5% fetal calf serum (HyClone) in plastic dishes or on nitrocellulose filters in bicameral systems (Costar, Corning, Inc.). The immortalized TAD-2 human thyroid cell line (34) , kindly provided by M. Vitale (Medical School, University Federico II), was cultured in DMEM supplemented with 10% fetal calf serum (HyClone). TSH and isobutyl methylxanthine (IBMX) were purchased from Sigma-Aldrich (St. Louis, MO), and TGF-␤ was from PeproTech (London UK). Cultures were kept at 37 C in a humidified atmosphere of 5% CO 2 and 95% air.
Mice and tissues
CD1 mice were housed and maintained in pathogen-free conditions. All animal experiments were performed according to approved institutional protocols. Staged mouse embryos were obtained by dissection of pregnant females.
CT1 human thyroid cancer tissue array slides were from SuperBioChips Laboratories (Yuksam-dong, Seoul, Korea). They consisted of 58 samples: nine benign thyroid tissues, 41 PTC, seven FTC, and one ATC. The following human thyroid tumors: one benign thyroid tissue, four PTC, two FTC, and nine ATC were provided by Guido Pettinato (Department of Biomorphological Sciences of the University Federico II).
IF and confocal microscopy
Tissues for IF were treated as previously described (7) . Deparaffinization, hydration, and antigen retrieval of tissue sections were performed by means of wax capture antigen retrieval solution (pH 6.0), according to manufacturer's instructions (Bio-Optica, Milano, Italy). Before the blocking reaction, sections were dipped in wax capture citrate buffer for 25 min at 98 C and washed in PBS and in PBS containing 0.2% Triton X-100 for 5 min.
Cultured cells grown on coverslips were fixed in 4% paraformaldehyde in PBS for 20 min, washed twice in 50 mM NH 4 Cl in PBS, and permeabilized for 5 min in 0.1% Triton X-100 in PBS. Alternatively, cells were fixed in methanol, at 4 C, for 30 min and in acetone, at Ϫ20 C, for 3 min. Fixed cells were treated as described (35) . Nuclei were stained with the DNA intercalator DRAQ5 (Alexis Corp., Lausen, Switzerland). IF analysis was performed at a confocal laser scanning microscope LSM 510 Meta (Zeiss, Gottingen, Germany). The of the argon ion laser was set at 488 nm, and that of the two HeNe lasers was set at 543 and at 633 nm. Fluorescence emission was revealed by 505-530 band pass filter for Alexa Fluor 488, by 560 -615 band pass filter for Alexa Fluor 546, and by 615 long pass filter for DRAQ5. Double and triple staining IF images were acquired separately in the green, red, and infrared channels at a resolution of 1024 ϫ 1024 pixels, with the confocal pinhole set to one Airy unit and then saved in TIFF format.
Western blotting
Cells grown in plastic dishes were lysed in Tris-buffered saline [150 mM NaCl, and 20 mM Tris-HCl (pH 7.5)], containing 1% Triton X-100; 30 g of total protein lysate were boiled for 5 min in Laemmli sample buffer and analyzed on 10% SDS-PAGE. Gels were then blotted onto nitrocellulose transfer membrane (Schleicher and Schuell GmbH, Dassel, Germany) using a BioRad apparatus (Bio-Rad Laboratories, Hercules, CA) as previously described (35) . For reprobing, nitrocellulose filters were rehydrated and stripped for 20 min at 37 C in Restore Western Blot Stripping Buffer (Pierce, Rockford, IL) and washed extensively with Tris-buffered saline with 0.1% Tween 20.
Quantitative RT-PCR
Neoplastic human thyroid tissues and normal adjacent tissues or the contra lateral normal thyroid lobe were obtained from surgical specimens and immediately frozen in liquid nitrogen. Thyroid tumors were collected at the Service d'Anatomo-Pathologie (Centre Hospitalier Lyon Sud, Pierre Bénite, France). All human tissue samples were obtained and used with institutional review board approval. Total RNA was extracted from tissues and cell cultures using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. The integrity of the RNA was assessed by denaturing agarose gel electrophoresis. One microgram of total RNA from each sample was reverse transcribed with QuantiTect Reverse Transcription kit (QIAGEN) using an optimized blend of oligo-dT and random primers according to the manufacturer's instructions. PCR was carried out on cDNA as previously described (36) .
To design a quantitative RT-PCR (qRT-PCR) assay, we used the Human ProbeLibrary system (Exiqon, Vedbaek, Denmark). Using the ProbeFinder assay design software (freely accessed on the web site http://www.roche-applied-science.com/sis/rtpcr/ upl/ezhome.html), we chose the best probe and primers pair.
Gene name, accession number, amplicon size, exon position, probe number (according to the numbering of Exiqon's Human ProbeLibrary kit), and primer sequences are listed in Table 1 .
The same procedure was used to choose the probe and primers for the housekeeping gene glucose 6-phosphate dehydrogenase (G6PD) (accession no. X03674). We opted for an amplicon of 106 nucleotides that spanned the 3rd and 4th exon. The probe number was 05, and the primer sequences were: G6PD forward, 5Ј-ACAGAGTGAGCCCTTCTTCAA-3Ј and G6PD reverse, 5Ј-GGAGGCTGCATCATCGTACT-3Ј. All fluorogenic probes were dual-labeled with 6-carboxy fluorescein at 5Ј-end and with a black quencher at the 3Ј-end. Real-Time Quantitative TaqMan   TABLE 1 . Gene name, accession no., amplicon size, exon position, probe no., and primer sequences 
Results
Expression of CDH16 gene in the thyroid gland
It has been reported that the expression of CDH16 is not limited to the kidney, because it can be detected also in the mouse thyroid gland (7) . We extended these observations and demonstrated that CDH16 protein was expressed in the human thyroid gland (Fig. 1 , A-D). We also tested whether the expression of CDH16 was maintained in thyroid cells cultured in vitro. To this aim, we searched for CDH16 expression in epithelial cell lines derived from rat (FRTL5, FRT, and PC Cl3) and from human (TAD-2) thyroids. By IF and confocal microscopy, we found that CDH16 protein was expressed both by the well-differentiated FRTL5 and by the poorly differentiated FRT rat thyroid cell lines (Fig. 1, E and F) . In these cells, the antibody stained the cell plasma membrane. On the contrary, no staining was present neither in the differentiated PC Cl3 rat cell line, neither in the human TAD-2 cell line (data not shown). WB confirmed the presence of a band of about 120 kDa in the cell lysate derived from FRTL5 and FRT cell lines, whereas no band was present in the case of the PC Cl3 and TAD-2 cell lines (Fig. 1G) . The expression of the Pax8 transcription factor was also evaluated. Pax8 was found to be present at different level in all cell lines, with the exception of the human TAD-2 cell line (Fig. 1G) . We then asked whether CDH16 colocalized with CDH1 on the plasma membrane of follicular cells, in the thyroid gland. Mouse and human tissue sections were stained by double IF using anti-CDH1 and anti-CDH16 antibodies. The two proteins colocalized to a large extent on the basolateral plasma membrane of both mouse and human thyrocytes (Fig. 2) .
To firmly assess that CDH16 protein was localized on the basolateral plasma membrane of thyrocytes, double IF staining was performed on mouse and human thyroid sections with antibodies anti-CDH16 and antisodium/iodide symporter (NIS), which is known to localize on the basolateral plasma membrane of thyrocytes (37) . Moreover, double immunofluorescence was performed on mouse thyroid sections and on FRT cells grown on filters in bicameral systems with antibodies anti-CDH16 and antizonula occludens-1 (ZO-1), a protein of the tight junctions that is expressed on the lateral-apical side of thyrocytes (38) . NIS and CDH16 fully colocalized on the basolateral plasma membrane of mouse and human thyroid sections, whereas ZO-1 and CDH16 localized at different sites of the plasma membrane, the former being at the apical domain, the latter at the basolateral (Supplemental Fig. 1 , 
CDH16 expression is dependent upon TSH
Because CDH16 protein was selectively expressed in the thyroid gland, other than in the kidney, we asked whether its expression was dependent upon TSH like other thyroid-restricted proteins, e.g. Pax8, NIS, and thyroperoxidase (32, 39, 40) . To this aim, FRTL5 cells were cultured in the presence or absence of TSH for 7 d and then examined for the expression of CDH16 and Pax8 by IF and confocal microscopy. In control cells, in the presence of TSH, anti-Pax8 antibodies stained the cell nuclei and anti-CDH16 antibodies stained the plasma membrane of the cells (Fig. 3, A-D) . After 7 d of TSH starvation, Pax8 staining was completely abolished, as expected (32) , and CDH16 staining was abolished as well (Fig. 3, E-H) . Two days after the readdition of TSH to the culture medium, Pax8 and CDH16 staining was restored (Fig. 3, I-L) . Readdition of dibutyryl cAMP (dbcAMP) (41) to the culture medium of TSH-starved cells mimicked the effect of TSH readdition (Fig. 3, M-P) . FRTL5 cell lysates, after 7 d of TSH starvation and 2 d of TSH or dbcAMP readdition, were also examined by WB (Fig. 3Q) . The results demonstrated that the presence of Pax8 protein, as well as that of CDH16, was dependent upon TSH and dbcAMP stimulation, in full agreement with the IF data.
CDH16 expression in the thyroid gland during mouse embryo development CDH16 is expressed in the kidney during embryonic development, and it was proposed to be required for kidney differentiation process (18) . We investigated whether CDH16 is expressed in the thyroid gland during mouse embryo development. Two thyroid-restricted transcription factors, Pax8 and Nkx2.1, both expressed in the thyroid primordium before E9.5 (42) , were used to identify the thyroid epithelial cells in mouse embryo sections. The time-dependent expression of CDH16 was also compared with that of CDH1, which is expressed very early in all endodermal epithelia (2). Thyroid follicular cells, which are derived from the endodermal epithelium of the ventral pharyngeal floor, express high levels of CDH1 at all developmental stages (6) .
At E9.5, the antibody against Pax8 stained nuclei of cells in the developing thyroid placode (Fig. 4, A and C) , anti-CDH1 antibody stained all the cells of the endodermal epithelium, including the Pax8 positive cells, whereas no staining was observed with anti-CDH16 antibody (Fig.  4, B and D) . At E10.5, Pax8 antibody stained the nuclei of cells in the thyroid bud (Fig. 4, E and G) , and CDH1 and CDH16 antibodies stained the cells in the developing thyroid bud (Fig. 4, F and H) . At E14.5 of mouse embryo development, the antibody against Nkx2.1 stained the nuclei of cells of the thyroid primordium (Fig. 4, I and K), the antibody against CDH1 stained all epithelial tissues (Fig.  4J) , and the antibody against CDH16 stained only the thyroid cells in the thyroid primordium (Fig. 4L) .
Expression of CDH16 in human thyroid tumors
Reduced expression of classical cadherins, CDH1 in particular, is associated with loss of differentiation and increased invasiveness of several types of neoplasms, including thyroid carcinomas (5) . It has been found that also the expression of CDH16 is severely reduced in RCC, which originate from kidney tubular epithelial cells (12) . We compared the expression of CDH1 and CDH16 in human thyroid carcinomas by double IF and by qRT-PCR. Sixty-four human thyroid tumors, 45 PTC, nine FTC, 10 ATC, and 10 nonpathological thyroids were used in IF (Table 2) . A small variability in the staining for CDH1 was observed in most of the PTC samples with loss of staining in only few of them, whereas a pronounced decrease was observed in most of the FTC samples compared with nonpathological thyroid sections; staining was almost absent in all ATC samples ( Fig. 5 and Table 2 ). A more dramatic decrease in CDH16 staining was observed in all tumors (Fig. 5) . Moreover, when observed at higher resolution, it was usually found that CDH1-negative cells were also negative for CDH16, whereas CDH16-negative cells could still be positive for CDH1 (Fig. 5) , indicating a more extensive loss of CDH16 and suggesting that its loss from the plasma membrane of the thyrocytes might have preceded that of CDH1. Quantitative RT-PCR analysis, which was performed on a separate collection of tumors (12 PTC and six ATC), indicated a variable and small down-regulation of CDH1 in the PTC samples and a much stronger down-regulation in all ATC samples with respect to controls (Fig. 5) . CDH16 expression was overall much more reduced in the PTC samples and was equally reduced in the ATC samples with respect to CDH1 (Fig. 5 ).
CDH16 expression is down-regulated by TGF-␤
TGF-␤ is a multifunctional cytokine that inhibits cell proliferation, induces tissue fibrosis, and promotes EMT, a process that directs polarized epithelial cells to differentiate into mesenchymal cells. EMT can occur in epithelial carcinoma cells along with cancer progression determining their invasive properties and metastatic potential. TGF-␤-induced EMT is characterized by an altered expression of cadherins, most notably loss of CDH1 (6) . Moreover, it has been found that the incubation with TGF-␤ leads to reduction in the level of CDH16 mRNA in renal tubular epithelial cells (43) . We tested the hypothesis that the down-regulation of CDH16 protein expression in thyroid epithelial cells might be concomitant to the occurrence of EMT. To this aim, FRTL5 cells were treated with TGF-␤ to induce EMT as previously described (44) . Cells were either grown on coverslips and analyzed by IF or grown on plastics, lysed, and subjected to WB. By 12-24 h of TGF-␤ treatment, a dramatic reduction in the expression of CDH16 was observed either by indirect IF and confocal microscopy or by WB (Fig. 6) . These data In nonpathological thyroid tissues, CDH1 and CDH16 colocalize on the plasma membrane of thyrocytes (A, B, A', and B'). CDH1 is present in PTC in almost all thyrocytes (C and C'), whereas CDH16 staining is observed only in restricted areas of the tumor (D and D', white arrowheads). In FTC, the expression of CDH1 is reduced (E and E'), and the staining of CDH16 is almost abolished, with the exception of few cells (F and F'). In ATC, the expression of CDH1 is much reduced (G), and that of CDH16 is abolished (H). However, in some restricted tumor areas of ATC, where the thyroid architecture is maintained, it is possible to detect the expression of CDH1 (G'), whereas fewer cells express CDH16 (H', white arrowhead). suggest that loss of CDH16 is part of the cohort of molecular alterations that occur during TGF-␤-induced EMT.
Expression of CRYAB in human thyroid tumors
The crystallins are members of the heat shock family of proteins and have predominantly been described as soluble lens proteins. CRYAB is a member of this family that is also expressed in many nonlenticular tissues, including heart, brain, skeletal muscles, skin, lung, kidney, and thyroid gland (45) (46) (47) . It was suggested that CRYAB might interact with the cytosolic tail of CDH16 (10) , and a consistent down-regulation of CRYAB in ATC was found (48) .
We decided to investigate the localization of CRYAB in the thyroid gland and to characterize the tumor-associated changes in the distribution of this protein by IF analysis. CRYAB distribution was also compared with that of CDH16. Nonpathological thyroid tissue exhibited a high intensity of CRYAB immunostaining, which was diffused on the entire cytoplasm (Fig. 7) . CDH16 staining over the tissue had an overall distribution similar to that of CRYAB, although it was confined to the plasma membrane of thyrocytes (Fig. 7) . CRYAB staining intensity was reduced in PTC and FTC sections, whereas CDH16 staining was detected in some cells of the PTC and few cells of the FTC samples (Fig.  7) . ATC-derived tissues were most often negative for CRYAB but were always negative for CDH16 immunostaining (Fig. 7) . Quantitative RT-PCR analysis of total RNA derived from nonpathological tissues and from 12 PTC and six ATC samples indicated that the expression of the CRYAB gene was down-regulated in the 12 PTC and in four of the six ATC tested (Fig. 7) .
Discussion
CDH16 has been considered for long time a kidney-specific cell adhesion molecule (13) (14) (15) (16) . We present here data that firmly support the notion that CDH16 is indeed expressed in the mammalian thyroid gland, that it is expressed during thyroid development, and that it is dramatically down-regulated in thyroid carcinomas. CDH16 is also expressed in cultured cell lines where its expression appears to be dependent upon TSH. Some of the thyroid-derived cell lines that we tested, either rat or human, do not express the protein, and we have no clear-cut explanation for that. However, it should not come as a surprise that a specific property of a differentiated cell might be lost in cultured cell lines. The TAD-2 cells neither express the Pax8 protein that we speculate might be necessary, although not sufficient, for CDH16 expression. In the PC Cl3 cells, which expresses Pax8, the defect in CDH16 protein expression could be either due to lack of protein synthesis or to increased degradation.
When we examined the fine distribution of CDH16 in the thyroid gland, we found that it is expressed by thyroid follicular cells, that it is distributed on the basolateral plasma membrane, and that it fully colocalizes with CDH1 and NIS. Moreover, it has an opposite distribution with respect to the apical tight junction protein ZO-1 in mouse thyroid follicles and in polarized FRT thyroid cells grown on filters in bicameral systems. It has been shown that the LI-cadherin, that belongs to the same cadherin family as CDH16, is coexpressed with E-cadherin during mouse development (49) and that it is able to bind CDH1 in heterotypic fashion (50) . The question arises of whether CDH16 colocalization with CDH1 might reflect a possible interaction between the two adhesion molecules and whether this might modulate the adhesive properties of thyrocytes. The demonstration that, when expressed in CHO cells, CDH16 promotes intercellular adhesion with strength similar to that of CDH1 (17) is suggestive of a potential role of CDH16 in follicular cell adhesion. This was also suggested by a previous study, in which a conditional knockout mouse of the CDH1 protein in the thyroid gland was generated and little effects on intercellular junction formation and on the overall follicular organization were observed (7) .
The expression of CDH16 is restricted to the thyroid, the kidney, and possibly few more tissues (18) . This tissue-selective gene expression is common to many other genes (51) , and it is likely dependent upon a specific combination of tissue-restricted transcription factors. Because CDH16 expression is mainly restricted to the thyroid and the kidney, it is tempting to speculate that transcription factors that are common to the two tissues might be responsible, at least in part, for its tissue selectivity. As a matter of fact, both kidney and thyroid express the Pax8 transcription factor, and preliminary bioinformatics analyses indicate the presence of potential Pax8-binding sites in the CDH16 promoter. Recently, data have been provided indicating that CDH16 is indeed under the transcriptional control of Pax8 (T. de Cristofaro, personal communication). It is also worth noting that the expression of CDH16, like that of other thyroid-restricted genes, is under the control of TSH as confirmed by the observation that dbcAMP treatment of TSH-starved cells mimics the TSH addition. The expression of Pax8 itself, postnatally, is under the control of TSH. It appears therefore possible that the TSH hormone, via the Pax8 transcription factor, might regulate the expression level of the CDH16 adhesion molecule. Data obtained with dog and human thyroid cell cultures indicated that also CDH1 expression might be under the control of the TSH hormone (52) . What for? It was speculated that there might be an important physiological role on the action of this pathway in proliferation and differentiation (52) . This hypothesis can be extended to the CDH16 protein. To get some insight into the function of CDH16, we explored the timing of its expression during thyroid development. We found that CDH16 expression in the thyroid gland starts from E10.5, i.e. about 4 -5 d before folliculogenesis. We speculate that the adhesive strength of CDH16 might play some role in follicle morphogenesis, possibly related to the unique organization of the thyroid gland, which is composed of individual, closed, functional units. CDH16 expression is maintained throughout adulthood, suggesting that it might be a differentiated feature of thyrocytes needed for the maintenance of the follicular structure. That CDH16 might be required in morphogenetic processes was first proposed for the kidney where CDH16 transcripts were detected in the epithelium of the Wolffian duct at E10.5 (18) . The analysis of the gene knockout mouse might shed light on these hypotheses. Functional studies in cultured cell lines, by either knocking-down or reexpressing CDH16, will also be needed to determine its role in thyroid cell biology.
A plethora of data indicates that CDH1 down-regulation in carcinomas is a hallmark of malignancy (53) , and many different mechanisms for CDH1 inactivation in malignant tumors were reported (21) . The correlation between loss of CDH1 function and tumor progression holds true also in the thyroid gland, and it is supported by several in vivo (5, 26 -28) and in vitro (54) studies. We find here that CDH16 is down-regulated in PTC. This is in full agreement with the results obtained by gene expression profiling of PTC (55) . Our results indicate that CDH16 down-regulation occurs also in ATC and in FTC, although further analyses are needed to firmly assess this result. Moreover, we find that the extent of CDH16 down-regulation is higher than that of CDH1 and that CDH16 loss of expression appears to be an early event occurring before, and independently of, the loss of CDH1. This is mostly relevant in the case of PTC, in which a significant reduction in the expression of CDH16 is observed, whereas the alterations in the expression of CDH1 are variable and often nonsignificant. These observations suggest that CDH16 might be a better marker than CDH1 (28) and that it might be used in combination with CDH1, to monitor the evolution of thyroid tumors. It should be noted, however, that the TSH levels in the patients at the time of surgery from which the samples were obtained was not known to us, and therefore, a potential TSH effect on CDH16 down-regulation should be taken into account.
The strong down-regulation of CDH16 after TGF-␤-induced EMT in differentiated FRTL5 cells suggests that CDH16 might be an early marker, and/or might play a role, in the EMT that occurs when a tumor progresses to a more malignant, invasive phenotype (56) . Functional studies are needed to establish the relation between expression of CDH16 and the tumor cell phenotype. Further studies are needed to evaluate whether CDH16 and its regulators and interactors can become valuable diagnostic and prognostic indicators, as well as potential therapeutic targets in follicular cell-derived thyroid carcinomas. The presence of circulating CDH16 proteolytic fragments, e.g. in the case of malignant thyroid (or kidney) carcinomas, might be evaluated in the light of the fact that the cadherin ectodomain could be a target of elevated protease activity in the tumoral microenvironment (57) .
Concerning the mechanism responsible for CDH16 decrease in thyroid tumors, the hypothesis that it might be due to loss of expression of the Pax8 transcription factor should be tested. Pax8 is expressed in various thyroid cancers; however, its pattern of expression is controversial. By qRT-PCR, it was demonstrated that PAX8 gene expression decreased to variable extent in both PTC and follicular carcinomas and that a strong decrease occurred in ATC (58) . However, CDH16 loss appears to be much more dramatic and constant than that of Pax8, suggesting that CDH16 reduction might be also under the control of other factors.
Finally, reduced expression of the CRYAB protein in thyroid tumors was found in this study, extending previous results (48) . However, the correlation between the down-regulation of CDH16 and that of CRYAB is not as strong in ATC as it is in PTC, raising doubts on the functional link between the two. Further evidence should be found in support of the notion that CRYAB is a cytosolic interactor of CDH16 (12) also in the light of the fact that we do not find a full colocalization of the two proteins in IF assays.
It will be important to uncover whether those aberrations that affect CDH1 during cancer progression, such as mutation, promoter methylation, and transcriptional repression, also occur to CDH16 (21) . Unraveling CDH16 regulatory and signaling pathways, molecular inducers, and effectors, in both physiological and pathological conditions, as it has been largely done for CDH1, is likely to be relevant to improve the power of anticancer strategies in thyroid neoplasms.
